Editorial
|
|
|
|
|
Regulators and industry have to deliver
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Doubtful efficacy in COPD but clear harms
|
|
|
|
|
|
|
|
|
|
|
|
Choose morphine and optimal laxative therapy instead
|
|
|
|
|
|
|
|
|
|
|
|
Sometimes beneficial, if used safely
|
|
|
|
Adverse Effects
|
|
|
|
|
Routine checking and patient empowerment
|
|
|
|
|
|
|
|
|
|
Potential harm of diagnostic tests
|
|
|
|
|
|
|
|
|
|
Beware risk factors for QT prolongation
|
|
|
|
|
|
|
|
|
|
Immunosuppressive effects
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Choice of treatment for locally advanced prostate cancer
|
|
|
|
Reviews
|
|
|
|
|
Effective treatments, but many adverse effects
|
|
|
|
|
|
|
|
|
|
HbA1c between 7 and 7.5 is fine
|
|
|
|
|
|
|
|
|
|